What Is KPV? The Peptide Inside KLOW

What KPV Actually Is

KPV is three amino acids: lysine, proline, valine. That is the entire molecule. For comparison, BPC-157 is fifteen amino acids and TB-500 is forty-three. KPV is small enough that the single-letter code for its sequence, K-P-V, became its name, which is why it looks like an acronym and is not one.

Those three residues are not arbitrary. They are the tail end of alpha-melanocyte-stimulating hormone, a thirteen-amino-acid hormone cut from the precursor protein proopiomelanocortin. Written out, alpha-MSH reads SYSMEHFRWGKPV. The last three letters are KPV, which is why the peptide also turns up in the literature as alpha-MSH(11-13). Everything interesting about KPV starts with the fact that it is a piece of a hormone rather than a designed drug.

Alpha-MSH does two very different things. It drives pigmentation, mostly by activating the MC1 receptor on melanocytes, and it damps inflammation through signaling in a wide range of immune and non-immune cells. For anyone interested in the second effect, the first one is a problem. A drug that reliably darkens skin is a hard sell as an anti-inflammatory. The research question through the 1990s and 2000s was whether the two activities could be separated, and the C-terminal tripeptide is the answer that kept working: in the models tested, KPV held onto anti-inflammatory activity while losing the melanotropic activity of the parent hormone.

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocrine Reviews. 2008;29(5):581-602. View study

One piece of housekeeping that matters more than it sounds: "KPV" is a common name, not a standardized drug name, and it gets applied to more than one substance. KPV free base and KPV acetate are chemically different starting materials. The FDA made a point of this in its 2026 review, noting that inconsistent naming for KPV-related substances is itself a safety issue, because a reference standard or a label can be pointing at something other than what the prescriber intended. There is also a close relative, KdPT, which is a different tripeptide derived from interleukin-1 beta and is not the same molecule.

How a Hormone Fragment Got a Name

The origin point is a 1989 paper in the FASEB Journal by Mary Hiltz and James Lipton at UT Southwestern, reporting that a COOH-terminal fragment of alpha-MSH carried anti-inflammatory activity on its own. Lipton had spent years on alpha-MSH as an antipyretic and anti-inflammatory neuropeptide. The 1989 result reframed the work: you did not need the whole hormone.

What followed was two decades of increasingly specific animal and cell work, mostly out of three groups. Lipton and Anna Catania in Milan mapped which inflammatory stimuli the peptides blocked and which they did not. Thomas Brzoska, Thomas Luger and colleagues in Münster pushed the dermatology and bowel-inflammation side. Didier Merlin at Emory, later Georgia State, worked out how KPV gets into intestinal cells at all.

Read that timeline honestly and one thing stands out. Thirty-seven years after the first paper, the literature is deep on cells and rodents and empty on humans. That is not a knock on the science. It is a description of where the science stopped.

How KPV Appears to Work

The most detailed mechanistic account comes from the Dalmasso paper. Working in Caco2-BBE and HT29-Cl.19A intestinal epithelial cell lines and in Jurkat human T cells, the group stimulated the cells with proinflammatory cytokines and then added KPV. At nanomolar concentrations, KPV inhibited activation of NF-kB and MAP kinase signaling and reduced proinflammatory cytokine secretion. Using radiolabeled KPV and competition experiments, they showed the peptide is carried into both epithelial and immune cells by PepT1, the di- and tripeptide transporter.

What KPV does not seem to do is act like a melanocortin receptor drug. In binding studies it did not displace radiolabeled alpha-MSH from rat brain tissue, murine melanoma cells or MC1-receptor-expressing macrophages, and unlike alpha-MSH it did not raise cyclic AMP in those macrophages. Pharmacological and genetic approaches have failed to pin the anti-inflammatory or wound-healing effects on MC2, MC3 or MC4 receptors. Kannengiesser found KPV still worked in mice carrying a nonfunctional MC1 receptor. Not everyone agrees the receptors are irrelevant: Land, in 2012, argued for an MC3-receptor role in human bronchial epithelial cells. The fair summary is that the target is unsettled and the intracellular route through PepT1 is currently the best-supported part of the story.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. View study

Why the Gut Keeps Showing Up

Search KPV and the results skew heavily toward the intestine. There is a reason for that, and it is the transporter. PepT1 is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease. A tripeptide that rides PepT1 therefore concentrates itself, at least in principle, in exactly the tissue that is inflamed. That is an unusually tidy piece of pharmacology, and it is why the gut work took off after 2008 rather than before.

The animal results were consistent. Dalmasso put KPV in the drinking water of mice with DSS-induced and TNBS-induced colitis and saw reduced incidence and lower proinflammatory cytokine expression. Kannengiesser, working in Münster, ran two different models, DSS colitis and CD45RB-high transfer colitis, and reported earlier recovery, better weight regain, fewer inflammatory infiltrates on histology, and lower myeloperoxidase activity in colonic tissue. In mice with a nonfunctional MC1 receptor, KPV treatment rescued the treated animals from death during DSS colitis.

Kannengiesser K, Maaser C, Heidemann J, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflammatory Bowel Diseases. 2008;14(3):324-331. View study

Then the field ran into delivery. Getting a tripeptide through the stomach and small intestine intact, in enough quantity, at the right place in the colon, is not trivial, which is why the 2017 Molecular Therapy paper wrapped KPV in hyaluronic-acid-functionalized nanoparticles inside a chitosan-alginate hydrogel rather than simply giving more of it by mouth. That detail is easy to skip past and it matters: a study design that needs a nanoparticle carrier is telling you something about what plain oral dosing does not accomplish.

This is also where the honest caveat belongs. Mouse colitis models are induced chemically or by cell transfer, they run over days, and they are a research tool, not a stand-in for a person with a diagnosed bowel disease. Nothing in this literature has been reproduced in a human clinical trial. If you have inflammatory bowel disease, the therapy that belongs at the center of your care is the one your gastroenterologist prescribes. Our broader position on this category is in how we approach gut-health peptides Read nextHow We Approach Gut-Health PeptidesMost GI care suppresses symptoms. Gut peptides aim at the barrier underneath. BPC-157 does the structural repair, glutathione defends against oxidative damage, and Thymosin Alpha-1 modulates gut immune tissue. Here is how a provider picks the layer you need.Read article , and the peptides we group there are listed on the gut health page.

Why KPV Sits Inside KLOW

PeRx does not offer a standalone KPV vial. The only way to get it here is KLOW, a four-peptide blend that also contains BPC-157, GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide and TB-500. That is a deliberate formulation choice rather than a merchandising accident, and the reasoning is worth spelling out because it is the part of this subject no research paper covers.

Recovery is not one process happening in one place. BPC-157 is the local component, associated in the literature with angiogenesis and growth-factor recruitment at the site of injury, and its background is covered in the BPC-157 guide Read nextBPC-157: The Complete Guide to the Body Protection CompoundA peptide discovered in a Croatian lab in the early '90s is now one of the most studied healing compounds in regenerative medicine. Here's what the science actually says, where it came from, and what you should know before starting.Read article . TB-500 works body-wide through actin regulation and cell migration, which is why the two get paired so routinely that we wrote a separate piece on it: why we pair BPC-157 and TB-500 Read nextWhy We Pair BPC-157 With TB-500 (and When BPC-157 Alone Is Enough)BPC-157 works fast and focal, strongest at a specific injury and in the gut. TB-500 works broad and systemic. The pairing is not automatic. Here is how a provider decides whether you need both, or whether BPC-157 on its own does the job.Read article . GHK-Cu, the copper-binding tripeptide covered in the GHK-Cu guide Read nextGHK-Cu Copper Peptide 2026: Skin, Hair & Tissue RepairHow GHK-Cu rebuilds collagen, influences thousands of genes, and helps skin and hair, plus the research, dosage, side effects, and how the injectable differs from topical copper-peptide skincare.Read article , carries the connective tissue and skin side of remodeling. KPV is the fourth angle, aimed at the inflammatory signaling that runs underneath all three.

There is a second reason KPV rides along rather than standing alone, and it is the evidence base. A peptide with no human data is a weaker candidate for a solo prescription than it is as one part of a blend built around BPC-157, which has the deepest research record of the four. KLOW is the step up from a three-peptide recovery stack for people already running BPC-157 and TB-500 who want the inflammatory and connective-tissue angles covered in the same injection. It is not a starter product, and for most people a single peptide is the more sensible first prescription.

What the FDA Panel Voted On

KPV had a strange month in July 2026, and the coverage of it was mostly wrong in one direction or the other. Here is the sequence.

A compounding pharmacy nominated KPV years ago for the 503A bulks list, the list of bulk drug substances that state-licensed 503A pharmacies are permitted to compound from for individual patients. The nomination was ambiguous about whether it covered KPV free base or KPV acetate, and it was later withdrawn. The FDA evaluated both forms anyway, on its own initiative. The nominated use was topical: cream and gel at 0.1 percent, for wound healing and inflammatory conditions such as psoriasis and eczema.

The agency staff review, dated May 12, 2026, came out against. Its reasoning was not that KPV looked dangerous. It was that the substance is not well characterized chemically under a standardized name, the extent of its actual use in compounding is unknown, and there is no information at all on KPV administered to humans by any route, which leaves both effectiveness and safety unassessable. FDA-approved therapies already exist for wounds and for inflammatory skin disease. On that basis the staff proposed not adding KPV to the list.

The Pharmacy Compounding Advisory Committee disagreed. On July 23, 2026, the first day of a two-day meeting, it voted 8 to 6 with one abstention to recommend KPV for the 503A bulks list. BPC-157, TB-500 and MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide also cleared that day, with Semax Explore PeRxSemax/SelankCognitive Clarity & Calm FocusView peptide and Epitalon Explore PeRxEpitalonThe Longevity PeptideView peptide following on July 24 and DSIP Explore PeRxDSIPDeep Sleep PeptideView peptide being the only one turned down. Going against the agency briefing document is rare, which is why the room reacted the way it did. The full tally and what it means for each peptide is in our write-up of the FDA panel vote Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe two-day FDA advisory meeting ended July 24, 2026 recommending six of seven peptides for compounding, BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and declining only DSIP, all against the FDA's own scientists. The full vote tally, and what it changes.Read article .

What the Evidence Does Not Show

Most of this article is animal and cell data. That deserves to be stated flatly rather than buried, because the gap between the KPV literature and a claim about what happens in your body is wide.

There are no published clinical studies of KPV in humans. The FDA searched for them across PubMed, Embase, ClinicalTrials.gov, DailyMed, Drugs@FDA and professional society sources and reported finding no data on KPV administered to people by any route. The nine references submitted with the original nomination included eight animal studies of alpha-MSH derivatives and one skin-permeation experiment on human cadaver skin. No pharmacokinetic or toxicokinetic studies of KPV free base or KPV acetate were identified either.

The safety picture is the same shape. A search of the FDA Adverse Event Reporting System through December 3, 2025 returned zero reports involving KPV, and a search of the Human Foods complaint system going back to 2004 found none. That is genuinely reassuring in one narrow sense and useless in another. Almost nobody reports adverse events for compounded products, and 503A pharmacies generally are not required to. Zero reports about a substance with no measured human exposure is an absence of information, not a clean bill of health.

One more limit worth knowing, because it is often quoted backwards online. A 2017 study in the Journal of Pharmaceutical Sciences found that KPV does not permeate human skin well on its own, and needed iontophoresis or microporation to reach the inner epidermal layers. That result cuts against topical KPV products, which is what the FDA nomination was actually about. It says nothing either way about a peptide delivered by subcutaneous injection, which is how KPV reaches circulation inside KLOW.

Pawar K, Kolli CS, Rangari VK, Babu RJ. "Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin." Journal of Pharmaceutical Sciences. 2017;106(7):1814-1820. View study

What would change the picture is straightforward and slow: human pharmacokinetic work, then controlled trials with a defined dose, route and endpoint. Researchers have been calling for exactly that for years. Until it exists, the correct posture toward KPV is interest without conviction.

How KPV Is Prescribed at PeRx

KPV reaches patients here only as part of KLOW. The vial holds all four peptides together at 3 mg, 10 mg, 3 mg and 3 mg per mL for BPC-157, GHK-Cu, KPV and TB-500 respectively, in a 5 mL vial. A typical 20-unit dose, which is 0.2 mL on an insulin syringe, delivers 0.6 mg of KPV alongside the other three. It is a subcutaneous injection, most often into the abdomen or the thigh.

The process is the same as any other prescription here. You complete an online intake, a licensed provider reviews it, and if KLOW is appropriate your PeRx provider will prescribe a protocol and send it to a US-based 503A compounding pharmacy. The vial arrives by FedEx overnight in cold packaging. Your card is saved at checkout and charged only if a provider approves the prescription. Store the vial in the refrigerator between 36 and 46 degrees Fahrenheit and keep it out of the freezer.

Common Questions